8:00 – 12 September 2026
Auditorium, 3rd Floor, F Building, FV Hospital
8:00 – 12 September 2026
Auditorium, 3rd Floor, F Building, FV Hospital
To provide the latest updates in this field and create a forum for professional exchange among experts, FV Hospital is organising the CME Medical Symposium “Updates on clinical evidence and international guideline for TROP2-targeting ADC in the treatment of advanced/metastatic triple-negative breast cancer”, with details as follows:
The symposium will focus on updates from ESMO and ASCO 2026, clinical data on TROP2-targeting ADCs, adverse event management, and key considerations for applying these therapies in clinical practice.
The programme will feature experts from Cho Ray Hospital and FV Hospital, who will share the latest clinical updates and practical perspectives on the treatment of advanced/metastatic triple-negative breast cancer.
We warmly invite doctors, pharmacists and healthcare professionals to attend this CME medical symposium to learn about the latest evidence on TROP2-targeting ADCs and discuss their potential application in the treatment of advanced/metastatic triple-negative breast cancer.
Registration:
To register for the programme, please visit: https://forms.gle/Zxja8nhyfhaLpakE7
CME certificates will be issued to healthcare professionals who attend the full programme and meet the requirements set by the Organising Committee.
| Time | Content | Speaker |
| 08:00 – 08:30 | Registration & Opening Remarks | Dr Vu Truong Son, MSc Medical Director |
| 08:30 – 09:10 | Advanced/Metastatic Triple-Negative Breast Cancer Ineligible for Immunotherapy: Current Treatment Landscape and Unmet Clinical Challenges | Dr Le Tuan Anh, PhD |
| 09:10 – 09:50 | ESMO and ASCO 2026 Updates: Clinical Evidence and Recommendations on TROP2-Targeting ADCs for Advanced/Metastatic TNBC | Dr Vo Kim Dien, MSc |
| 09:50 – 10:00 | Break | |
| 10:00 – 10:40 | Mechanism of Action and Adverse Event Management of TROP2-Targeted ADC Therapy | Pharmacist Nguyen Thi Khanh Van, MSc |
| 10:40 – 11:20 | Application of Clinical Trial Data in Personalised Treatment for Patients with mTNBC Ineligible for Immunotherapy | Dr Vo Thi Phuong Thao, MSc |
| 11:20 – 12:00 | Discussion | Chairperson, Speakers and Participants |
| 12:00 – 13:00 | Lunch Closing Remarks |